EQL chooses to postpone the list change to Nasdaq Stockholm
EQL Pharma revises the schedule for the planned list change from Spotlight Stock Market to Nasdaq Stockholm's main list, with the goal that the list change will be carried out after the summer of 2021 instead of the first quarter of the financial year 2021/22 as previously communicated.The decision to postpone the list change is due to the prioritization of the acquisition of seven product licenses in Denmark during the spring and winter, which was announced on March 15, 2021. Through that prioritization, the company needed to move resources from the listing process to the acquisition. This